Categories: December 09

Quant Snapshot: Tecsys Inc. (TSX:TCS)

Underlying Data

1. Price to sales: 0.22

As of Q3 2009 Tecsys Inc. had 12.65 million shares outstanding. The price as of May 29th, 2009 was C$1.66. This gives The Company a market capitalization of $21 million. In the trailing four quarters, sales totaled $42.93 million.

2. Cash to Market Cap: 36%

As of Q3 2009 reported cash and short term investments were $7.5 million.

3. Debt to market Cap: $100,000

As of Q3 2009 reported long term debt was $100,000.

4. Trailing Three year growth rate: 31.5%

Sales growth from annual report $26,124,930 in 2005. Sales grew to $59,380,354 in 2008.

5. Enterprise Value to Sales: 19.6%

Enterprise Value as of May 29, 2009 is $13.6 million, based on a market cap of $21 million plus $100,000 long term debt , minus cash and short term investments of of $7.5 million. Sales for the trailing four quarters totaled $42.93 million.

All financial information about Versatile Systems is gleaned from
their filings with the System for Electronic Document Analysis and
Retrieval (SEDAR)
All calculations are based on The Company’s closing share price as of
close May 29, 2009: $1.66
Sales from trailing four quarters: $42.93million
Cash and short term investments as of June 30, 2009 (3rd Quarter)
: $7.5 million
Shares outstanding: 12.65 million.

Staff

Recent Posts

Perimeter Medical Imaging wins price target raise from this analyst

In an April 8 note, Paradigm Capital analyst Scott McAuley maintained his “Speculative Buy” rating on Perimeter Medical Imaging AI… [Read More]

2 hours ago

The analyst still loves Kits Eyecare

Beacon Securities analyst Doug Cooper said preliminary first-quarter results from Kits Eyecare (Kits Eyecare Stock Quote, Chart, News, Analysts, Financials… [Read More]

2 hours ago

Blackline Safety shareholders should take the deal, this analyst says

Ventum Capital Markets analyst Amr Ezzat moved Blackline Safety (Blackline Safety Stock Quote, Chart, News, Analysts, Financials TSX:BLN) to “Tender”… [Read More]

16 hours ago

Is The FUTR Corporation still a buy?

Research Capital analyst Greg McLeish maintained his “Speculative Buy” rating and $3.00 target on The FUTR Corporation (The FUTR Corporation… [Read More]

21 hours ago

This investor likes Vanguard FTSE right now

In an appearance on BNN Bloomberg Market Call on April 2, RN Croft Financial Group portfolio manager Richard Orrell highlighted… [Read More]

1 day ago

This new development makes WELL Health worth more, analyst says

In an April 8 note, Stifel analyst Justin Keywood maintained his “Buy” rating and C$8.00 target on WELL Health Technologies… [Read More]

1 day ago